BridgeBio Pharma, Inc.BBIO
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $579.96M, growing 355.2% year-over-year. TTM net income stood at $-729.88M (7.8% contraction). Quarterly EBITDA was $-104.77M and operating income was $-105.96M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze BBIO growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters